Item 1.01 Entry into a Material Definitive Agreement.

Lucido Subscription Agreement

On January 12, 2022, BioCorRx Inc., a Nevada corporation (the "Company"), entered into a Subscription Agreement (the "Lucido Subscription Agreement") with Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017, managed by Mr. Louis Lucido, a member of the Company's Board of Directors (the "Board").

Although the Lucido Subscription Agreement was dated January 3, 2022 and signed on January 4th, it did not become effective until the aggregate purchase price owed pursuant to the Lucido Subscription Agreement was paid in cash to the Company on January 12, 2022.

Pursuant to the Lucido Subscription Agreement, Mr. Lucido purchased shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), in the aggregate amount of $500,000 at a purchase price of $4.35 per share (the "Purchase Price"), for a total of 114,943 shares of Common Stock.

Galligan Subscription Agreement

On January 19, 2022, the Company entered into a Subscription Agreement (the "Galligan Subscription Agreement" and, together with the Lucido Subscription Agreement, the "Agreements") with The J and R Galligan Revocable Trust, managed by Mr. Joseph Galligan, a member of the Company's Board.

Although the Galligan Subscription Agreement was dated January 3, 2022 and signed on January 11th, it did not become effective until the aggregate purchase price owed pursuant to the Galligan Subscription Agreement was paid in cash to the Company on January 19, 2022.

The terms and conditions of the Galligan Subscription Agreement (including the number of shares of Common Stock purchased and the Purchase Price) are substantially the same as the Lucido Subscription Agreement.

The Company sold a total of 229,886 shares of Common Stock for gross proceeds of $1 million.

The foregoing description of the Agreements does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the form of the Agreements a copy of which is attached hereto as Exhibit 10.1, and incorporated herein by reference.






2

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.

The following documents are filed as exhibits to this current report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the Commission filing that included such document.





Exhibit
No.        Description
  10.1       Form of Subscription Agreement by and between BioCorRx Inc. and each
           of the Lucido and Galligan Trusts initially effective January 12,
           2022
104        Cover Page Interactive Data File (formatted as inline XBRL).





3

© Edgar Online, source Glimpses